Actinium Announces Webinar to Discuss Results of the Actimab-A Phase 1 Trial and Key Findings From the HuM195-Alpha Program

Key Scientific Advisors to Provide Perspective on Latest Results and Discuss Future Development Opportunities

NEW YORK, NY -- (Marketwired) -- 05/18/16 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of patients with advanced cancers, announced today that the Company will host a webinar to discuss results of the Phase 1 portion of the Actimab-A Phase 1/2 trial. The webinar will include a discussion of the Actimab-A Phase trial results, certain key findings of the HuM195-Alpha program enabled by the latest Actimab-A results, potential future development opportunities and next steps for the upcoming Phase 2 portion of the Actimab-A trial.

Actimab-A is an alpha particle radioimmunotherapy being developed for patients over the age of 60 who are newly diagnosed with acute myeloid leukemia (AML). Actimab-A is the second generation therapy from the HuM195-Alpha program, which Actinium licensed from Memorial Sloan Kettering Cancer Center (MSK). The current Phase 1/2 trial for Actimab-A is the fourth clinical trial under the HuM195-Alpha program with over 85 patients treated thus far as part of this program.

Webinar Information:

Scientific Advisors:

  • Dr. Joseph Jurcic, M.D., Professor of Clinical Medicine, Columbia University Medical Center; Director, Hematologic Malignancies Section, Division of Hematology/Oncology
  • David Scheinberg, M.D. Ph.D., Chair Molecular Pharmacology Program, Sloan Kettering Institute; Director, Experimental Therapeutics Center; Vincent Astor Chair

Company Speakers:

  • Dragan Cicic, M.D., Chief Medical Officer, Actinium Pharmaceuticals
  • Sandesh Seth, Executive Chairman, Actinium Pharmaceuticals

Date: June 1, 2016
Time: 8:00 am EST
Webcast Link:

Participant Toll-Free Dial-In Number:   (844) 309-0611
Participant International Dial-In Number:   (574) 990-9939

The live webcast can be accessed in the Investor Relations section of Actinium's website and an archived webcast will be available for playback.

Sandesh Seth, Actinium's Executive Chairman, stated, "Actinium is deeply committed to the development of Actimab-A and our HuM195-Alpha program as we believe our targeted approach of delivering alpha particles holds significant promise in AML and potentially other indications where there are serious unmet patient needs. We look forward to hosting this webinar to discuss the safety and efficacy results of Actimab-A from the Phase 1 portion of the ongoing Phase 1/2 trial. We will also be providing further insight into the potential development strategy for Actimab-A in the light of key findings from our HuM195-Alpha program which were enabled by the trial results."

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is currently in a single arm, multicenter trial Phase 1/2 trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, lintuzumab, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. ( is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.

Source: Actinium Pharmaceuticals